Form 4: Cogent Biosciences Director Receives Stock Options

Karen Jean Ferrante, a Director at Cogent Biosciences, Inc., was granted stock options as part of her compensation for services.

Summary

• Karen Jean Ferrante, a Director at Cogent Biosciences, Inc. (COGT), received a grant of stock options on April 1, 2026.
• The options have an exercise price of $35.24 and are exercisable starting April 1, 2026, with an expiration date of April 1, 2036.
• A total of 686 options were granted.
• These options were issued in lieu of cash compensation for services rendered as a director, under the company's non-employee director compensation plan.
• The number of options was determined by dividing the quarterly cash compensation by the Black-Scholes value of a single option at the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Director compensation is being provided in the form of equity, aligning director interests with shareholders.
• The stock options have a long exercise period (10 years), providing potential for future value appreciation.

Negatives

• The exercise price of $35.24 indicates a significant increase in share price is needed for the options to be in-the-money.

Risks

• The value of the stock options is subject to market volatility and the company's future performance.
• If the company's stock price does not exceed $35.24 per share, the options may expire worthless.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and its ability to reach or exceed the $35.24 exercise price by April 1, 2036.

Management Comments

• The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan.
• The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

Industry Context

StockSavvy.ai notes that the use of stock options for director compensation is a common practice in the biotechnology and pharmaceutical sectors, aiming to align executive and director incentives with long-term shareholder value creation. The specific exercise price reflects the company's valuation at the time of the grant.

Related Party Transactions

• The issuance of stock options to Director Karen Jean Ferrante in lieu of cash compensation is a related party transaction.

Stakeholder Impact

• Shareholders: The issuance of options dilutes existing share ownership, but also aligns director incentives with stock performance.
• Employees: No direct impact mentioned.
• Management: Standard compensation practice.
• Creditors: No direct impact mentioned.

Next Steps

• Karen Jean Ferrante may exercise her stock options if the company's stock price exceeds $35.24 before April 1, 2036.

Key Dates

Keywords

Cogent Biosciences, COGT, Form 4, Stock Options, Director Compensation, SEC Filing, Equity Award